California's top court refused to hold Gilead liable for delaying a safer HIV drug to protect its franchise – a win for ...

Now that we are trying to complete and devise some efforts about how to follow those requirements, it's sometimes being ...

The FDA selected three more technologies for its READI-Home Innovation Challenge, including home blood collection from Becton ...

But if the mandatory Most Favored Nation payment model was always meant primarily as a stick to coerce manufacturers into ...

Amid ongoing geopolitical complexities and “profound transformations” affecting the pharmaceutical industry, French ...

CoreCare CEO and longevity medicine doctor Hillary Lin said that the evidence backing testing for hypertension and diabetes, ...

The Vaccines and Related Biological Products Advisory Committee recommended the same influenza A and B strains found in the ...

The company said it plans to file for approval of the azacitidine/cedazuridine combination pill in myelodysplastic syndromes ...

Orifarm has today unveiled a five-year plan that will see it push into new markets across Europe, with a “significant ...

TL1A inhibition is a competitive area of R&D. Merck has the lead in IBD with tulisokibart, and new Phase II data support a ...

The FDA urged sponsors to “step up and start doing the studies” during a workshop that was a return to more science-based ...

IL-4 and TSLP with Pfizer’s trispecific antibody, which the firm has moved into Phase III studies in two indications, ...